23andMe Sees Unusually High Options Volume (NASDAQ:ME)

23andMe Holding Co. (NASDAQ:ME) was the recipient of unusually large options trading activity on Wednesday. Traders bought 7,134 call options on the stock. This represents an increase of approximately 812% compared to the typical volume of 782 call options.

Institutional Investors Weigh In On 23andMe

Several institutional investors and hedge funds have recently made changes to their positions in the stock. FNY Investment Advisers LLC acquired a new position in shares of 23andMe in the 4th quarter valued at $26,000. Leavell Investment Management Inc. purchased a new stake in 23andMe during the 4th quarter valued at about $32,000. MassMutual Private Wealth & Trust FSB acquired a new position in shares of 23andMe in the fourth quarter valued at about $40,000. Virtu Financial LLC purchased a new position in shares of 23andMe in the fourth quarter worth about $49,000. Finally, Shay Capital LLC lifted its holdings in shares of 23andMe by 71.7% during the fourth quarter. Shay Capital LLC now owns 702,530 shares of the company’s stock worth $2,283,000 after purchasing an additional 293,358 shares during the period. 36.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 23andMe in a research report on Friday, March 7th.

23andMe Stock Performance

Shares of NASDAQ ME opened at $1.76 on Friday. 23andMe has a fifty-two week low of $1.34 and a fifty-two week high of $12.76. The company has a market cap of $47.22 million, a PE ratio of -0.11 and a beta of 1.19. The business has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $3.99.

23andMe (NASDAQ:ME) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 170.07%.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.